Skip to content
Tagged COVID-19 Biotechnology SARS-CoV-2 Life Science cancer CORONAVIRUS pandemic
BioXone

BioXone

rethinking future

March 7, 2026
  • About
  • BiotechTodayNews
    • IndiaWeekly Biotech News of India
    • WorldWeekly Biotech News of The World
  • DNA-TalesArticles
    • BiotechnopediaInteresting articles written by BioXone members and associates.
    • Scientists’ CornerArticles from the pioneers of Biotechnology.
    • Cellular CommunicationInterview of greatest researchers’ in the field.
  • Myth-LysisFact Check
  • Signalling PathwayCareer related updates
    • ExaminationsExamination related articles.
    • Job and InternshipJobs and Internship related articles.
  • Courses
  • Contact

Most Viewed This Week

October 17, 2023October 16, 2023

The Corrosion Prediction from the Corrosion Product Performance

1
October 1, 2023September 30, 2023

Nitrogen Resilience in Waterlogged Soybean plants

2
September 28, 2023September 28, 2023

Cell Senescence in Type II Diabetes: Therapeutic Potential

3
September 26, 2023September 25, 2023

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

4
September 25, 2023September 25, 2023

AI Literacy in Early Childhood Education: Challenges and Opportunities

5
September 22, 2023October 1, 2023

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

6

Search Field

Subscribe Now

  • Home
  • BiotechToday
  • Nano catalytic tumour therapy by single-atom catalysts

Neurodegeneration can now be cured by improving Autophagy pathways

Life Sciences Project Research Associate Job With Rs. 47,000 pm at RCB

Nano catalytic tumour therapy by single-atom catalysts
  • BiotechToday
  • World

Nano catalytic tumour therapy by single-atom catalysts

bioxone January 26, 2021January 26, 2021

Rohit Bhattacharjee, Amity University, Kolkata

Recently, single‐atom catalysts (SACs) are receiving increasing attention in varied chemical process fields, and meantime, rising nano catalytic drugs provide a unique tumor therapy modality while not victimizing harmful chemo drugs. The distinct properties of SACs, like exactly situated metal centers, identical coordination setting, tailorable composition and structure, and versatile practicality, build them promising candidates for chemical process tumor medical care. 

There are some foremost recent advances in nano catalytic tumor medical care by using various forms of SACs, particularly their outstanding achievements in different categories of nano catalytic tumor modes, like chemodynamic therapy, photodynamic therapy, sonodynamic therapy, and parallel chemical process therapy. Thermodynamic therapies involve chemical reaction processes, photodynamic therapies involve light energy to accelerate chemical reaction processes, sonocatalytic therapies involve ultrasound in chemical reactions, and parallel chemical process therapies involve two or more chemical reactions occurring simultaneously. These are reviewed by minute observation in the construction of catalytic platforms of nanoparticles and their mechanism. Thereafter a focused outline and outlook is provided finally to stipulate the views and also the remaining challenges for the longer term style and engineering of SACs for tumor therapy.

Also read: Neurodegeneration can now be cured by improving Autophagy pathways

Source:- https://onlinelibrary.wiley.com/doi/10.1002/smll.202004467

  • The Corrosion Prediction from the Corrosion Product Performance
  • Nitrogen Resilience in Waterlogged Soybean plants
  • Cell Senescence in Type II Diabetes: Therapeutic Potential
  • Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP
  • AI Literacy in Early Childhood Education: Challenges and Opportunities

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Related

Tagged chemodynamic therapy nanocatalytic drugs parallel chemical process therapy photodynamic therapy single-atom catalysts (SACs) sonodynamic therapy tumour therapy

One thought on “Nano catalytic tumour therapy by single-atom catalysts”

  1. Pingback: Direct Air Capture: Can wartime-level investment in novel tech slow down Global Warming? - BioXone

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Next Post
  • Job and Internship
  • Signaling Pathway

Life Sciences Project Research Associate Job With Rs. 47,000 pm at RCB

bioxone January 26, 2021

-Shristi Sharma, Team bioXone Life Sciences Project Research Associate Job With Rs. 47,000 pm at RCB. RCB is hiring PhD life science candidates. Eligible candidates can apply online for the Project Research Associate vacancy. Regional Centre for Biotechnology job vacancy for PhD details below: RCB Vacancy Details Advt. No. 02/Project/2021/HR Name of Job: Project Research […]

Related Post

  • BiotechToday
  • World

Priority Review for Pfizer’s tick-borne encephalitis vaccine in the US

bioxone March 4, 2021March 4, 2021

Devyani Goswami, Amity University Kolkata Nanette Cocero, global president, vaccines, of Pfizer announced that their tick-borne encephalitis vaccine (TBE) has been approved for a priority review from the US Food and Drug Administration (FDA).  Once approved the vaccine promises to cure tick-borne encephalitis epidemics all across the US. The vaccine has to be subjected twice […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • BiotechToday
  • World

Can the COVID-19 vaccine integrate with the human genome?

bioxone July 14, 2021July 14, 2021

Madhavi Bhatia, NIPER Guwahati SARS-CoV-19, well known as a severe acute respiratory syndrome that affects mainly the respiratory system of humans has become a global pandemic. Various vaccines have been approved worldwide to curb the disease. In Australia, the Pfizer and Moderna vaccine is approved. Both these vaccines are a type of encapsulated mRNA vaccine, […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • BiotechToday
  • World

Poor man’s diet, millets can lower the risk of diabetes

BioTech Today July 31, 2021July 31, 2021

Parnad Basu, Amity University Kolkata Diabetes mellitus type 2: It is the most common type of diabetes that happens to middle-aged or older people though kids suffering from childhood obesity are also at risk. In case of the type 2 diabetes, insulin (a hormone created in the pancreas) doesn’t get used by our cells, which […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Breaking News

The Corrosion Prediction from the Corrosion Product Performance

Nitrogen Resilience in Waterlogged Soybean plants

Cell Senescence in Type II Diabetes: Therapeutic Potential

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

AI Literacy in Early Childhood Education: Challenges and Opportunities

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

Exogenous Klotho as a Cognition Booster in Aging Primates

Terms and Conditions
Shipping and Delivery Policy
Cancellation and Refund Policy
Contact Us
Privacy Policy